AMENDMENTS

In the Claims:

Claims 1-27 (cancelled):

Claim 28 (Currently amended): A method of simultaneously genotyping multiple samples in a single round of hybridization, the method comprising:

- 1) incubating a microarray of polynucleotide samples from multiple individuals with a probe mixture of oligonucleotides of known sequence, wherein
- a) the microarray contains a plurality of samples containing genotypes of interest with each sample in a distinct location,
- b) each sample has polynucleotides with a defined segment containing a marker selected from a marker for a gene and markers for one or more allelic variants of the gene,
- c) the oligonucleotides in the probe mixture consist essentially of oligonucleotides of known sequence and length and having sequences specifically complementary to those within the defined segments for each sample for which a genotype is to be determined, wherein the oligonucleotides complementary to the polynucleotides are selected from those with sequences complementary to a segment containing the marker for (1) a gene, (2) one or more allelic variants of the gene, and (3) a gene and one or more allelic variants of the gene, and also consisting essentially of, optionally, control oligonucleotides,
- d) the incubating forms hybrids of polynucleotides of the array microarray and complementary oligonucleotides and allows discrimination at single nucleotide resolution; and

2) detecting stable hybrids formed during the incubation, if any, wherein the formation of a hybrid or lack of formation of a hybrid after a single round of hybridization at the distinct location is indicative of a genotype of a mammal the individual.

Claim 29 (Original): The method of claim 28 wherein the polynucleotide samples of the microarray are amplification products.

Claim 30 (Original): The method of claim 29, wherein the amplification products are produced by a polymerase chain reaction (PCR) method.

Claim 31 (Currently amended): The method of claim 30 wherein the plurality of elasses samples of polynucleotides is at least 10.

Claim 32 (Original): The method of claim 28 wherein an allele of the gene is associated with a disease.

Claim 33 (Original): The method of claim 32 wherein the disease is a human disease.

Claim 34 (Original): The method of claim 32 wherein the gene is human and is selected from the group consisting of β -globin, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), and Galactose-1-Phosphate Uridyltransferase (Gal-1-PU).

Claim 35 (Original): The method of claim 28 wherein the microarray is on a surface containing at least 1000 locations per square centimeter.

Claim 36 (Currently amended): The method of claim 28 wherein the <u>probe</u> mixture of oligonucleotides of known sequence comprises oligonucleotides with ten different sequences.

Claim 37 (Original): The method of claim 28 wherein the oligonucleotides in the mixture are between about 10 and 30 nucleotides in length.

Claim 38 (Original): The method of claim 28 wherein the distinct segment is between about 40 and about 1000 nucleotides.

Claim 39 (Original): The method of claim 28 wherein the incubating is in an aqueous solution comprised of salts and detergent.

Claim 40 (Original): The method of claim 28 wherein hybridizing is performed at a temperature about 10 °C below the melting temperature of the stable hybrids.

Claim 41 (Original): The method of claim 28 wherein the oligonucleotides of known sequence are labeled.

Claim 42 (Original): The method of claim 41 wherein the label is fluorescent.

Claim 43 (Original): The method of claim 28, wherein samples from homozygotes and samples from heterozygotes are distinguishable.

Claim 44 (Currently amended): The method of claim 28 wherein the plurality of elasses samples of polynucleotides is at least 5,000.

Claim 45 (Original): The method of claim 28 wherein the individual specimens are neonatal blood samples.

Claim 46 (Currently amended): The method of claim 28 wherein the mammal individual is a human.